The laboratory and the new oral anticoagulants

Research output: Contribution to journalArticle

Abstract

Measurements of the effect of NOAs are indicated in several situations: (a) patients with adverse events (i.e., thrombotic/hemorrhagic), particularly those who present with overdosage owing to excessive drug intake or decreased clearance; (b) patients undergoing surgical procedures for ensuring that no residual drug remains in the circulation; (c) patients requiring anticoagulation reversal because of life-threatening hemorrhage; (d) patients with renal insufficiency, who are likely to accumulate the drug in the circulation; (e) patients with liver failure, because NOAs are metabolized by the liver; (f) patients taking other drugs that might increase/decrease the effects of NOAs via drug- drug interactions. The choice of tests is based on such characteristics as availability, linearity of the dose- response curve, standardization, and responsiveness to increasing drug dosage. Practitioners need to be aware that NOAs can interfere with the measurement of common hemostasis parameters.

Original languageEnglish
Pages (from-to)353-362
Number of pages10
JournalClinical Chemistry
Volume59
Issue number2
DOIs
Publication statusPublished - Feb 2013

Fingerprint

Anticoagulants
Pharmaceutical Preparations
Liver
Drug dosage
Drug interactions
Standardization
Liver Failure
Hemostasis
Drug Interactions
Renal Insufficiency
Availability
Hemorrhage

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

The laboratory and the new oral anticoagulants. / Tripodi, Armando.

In: Clinical Chemistry, Vol. 59, No. 2, 02.2013, p. 353-362.

Research output: Contribution to journalArticle

@article{4c558db0e2a54d148d5039df8df87ad6,
title = "The laboratory and the new oral anticoagulants",
abstract = "Measurements of the effect of NOAs are indicated in several situations: (a) patients with adverse events (i.e., thrombotic/hemorrhagic), particularly those who present with overdosage owing to excessive drug intake or decreased clearance; (b) patients undergoing surgical procedures for ensuring that no residual drug remains in the circulation; (c) patients requiring anticoagulation reversal because of life-threatening hemorrhage; (d) patients with renal insufficiency, who are likely to accumulate the drug in the circulation; (e) patients with liver failure, because NOAs are metabolized by the liver; (f) patients taking other drugs that might increase/decrease the effects of NOAs via drug- drug interactions. The choice of tests is based on such characteristics as availability, linearity of the dose- response curve, standardization, and responsiveness to increasing drug dosage. Practitioners need to be aware that NOAs can interfere with the measurement of common hemostasis parameters.",
author = "Armando Tripodi",
year = "2013",
month = "2",
doi = "10.1373/clinchem.2012.189704",
language = "English",
volume = "59",
pages = "353--362",
journal = "Clinical Chemistry",
issn = "0009-9147",
publisher = "American Association for Clinical Chemistry Inc.",
number = "2",

}

TY - JOUR

T1 - The laboratory and the new oral anticoagulants

AU - Tripodi, Armando

PY - 2013/2

Y1 - 2013/2

N2 - Measurements of the effect of NOAs are indicated in several situations: (a) patients with adverse events (i.e., thrombotic/hemorrhagic), particularly those who present with overdosage owing to excessive drug intake or decreased clearance; (b) patients undergoing surgical procedures for ensuring that no residual drug remains in the circulation; (c) patients requiring anticoagulation reversal because of life-threatening hemorrhage; (d) patients with renal insufficiency, who are likely to accumulate the drug in the circulation; (e) patients with liver failure, because NOAs are metabolized by the liver; (f) patients taking other drugs that might increase/decrease the effects of NOAs via drug- drug interactions. The choice of tests is based on such characteristics as availability, linearity of the dose- response curve, standardization, and responsiveness to increasing drug dosage. Practitioners need to be aware that NOAs can interfere with the measurement of common hemostasis parameters.

AB - Measurements of the effect of NOAs are indicated in several situations: (a) patients with adverse events (i.e., thrombotic/hemorrhagic), particularly those who present with overdosage owing to excessive drug intake or decreased clearance; (b) patients undergoing surgical procedures for ensuring that no residual drug remains in the circulation; (c) patients requiring anticoagulation reversal because of life-threatening hemorrhage; (d) patients with renal insufficiency, who are likely to accumulate the drug in the circulation; (e) patients with liver failure, because NOAs are metabolized by the liver; (f) patients taking other drugs that might increase/decrease the effects of NOAs via drug- drug interactions. The choice of tests is based on such characteristics as availability, linearity of the dose- response curve, standardization, and responsiveness to increasing drug dosage. Practitioners need to be aware that NOAs can interfere with the measurement of common hemostasis parameters.

UR - http://www.scopus.com/inward/record.url?scp=84873114043&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873114043&partnerID=8YFLogxK

U2 - 10.1373/clinchem.2012.189704

DO - 10.1373/clinchem.2012.189704

M3 - Article

C2 - 23043068

AN - SCOPUS:84873114043

VL - 59

SP - 353

EP - 362

JO - Clinical Chemistry

JF - Clinical Chemistry

SN - 0009-9147

IS - 2

ER -